Abstract
In the last years, PKC has become an attractive target for the treatment of cancer patients given its widely described role in carcinogenesis and tumor promotion. Despite the extensive research conducted on these phorbol ester receptors there is only limited knowledge about the contribution of each individual PKC isozyme in malignant transformation, mainly due to the different roles of each isozyme and their tissue-specificity. This diversity provides the unique opportunity to develop specific pharmacological agents, but the complex nature of the signaling pathways activated by different PKCs challenges selective drug therapies. Currently, several classes of PKC inhibitors including small molecule kinase inhibitors, biologic modulators, and anti-sense oligonucleotides are being evaluated for the treatment of different cancers where PKC isozymes were found to be deregulated as lung, colon, skin, prostate, and breast malignancies. In this article we will review which PKC isoforms are deregulated in different human cancers and summarize the mechanism of action of some of the major PKC modulators, analyzing the strengths and weaknesses of each one in the clinical setting.
Keywords: Cancer, clinical trials, PKC, tumor promotion, malignant transformation, specific pharmacological agents, anti-sense oligonucleotides, protein kinase C (PKC), therapeutic target, cell membrane receptors, several signaling cascades, cell cycle arrest, normal mammary cells, matrix metalloproteinases (MMP)
Current Pharmaceutical Biotechnology
Title: The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Volume: 12 Issue: 11
Author(s): F. Coluccio Leskow, M. A. Krasnapolski and A. J. Urtreger
Affiliation:
Keywords: Cancer, clinical trials, PKC, tumor promotion, malignant transformation, specific pharmacological agents, anti-sense oligonucleotides, protein kinase C (PKC), therapeutic target, cell membrane receptors, several signaling cascades, cell cycle arrest, normal mammary cells, matrix metalloproteinases (MMP)
Abstract: In the last years, PKC has become an attractive target for the treatment of cancer patients given its widely described role in carcinogenesis and tumor promotion. Despite the extensive research conducted on these phorbol ester receptors there is only limited knowledge about the contribution of each individual PKC isozyme in malignant transformation, mainly due to the different roles of each isozyme and their tissue-specificity. This diversity provides the unique opportunity to develop specific pharmacological agents, but the complex nature of the signaling pathways activated by different PKCs challenges selective drug therapies. Currently, several classes of PKC inhibitors including small molecule kinase inhibitors, biologic modulators, and anti-sense oligonucleotides are being evaluated for the treatment of different cancers where PKC isozymes were found to be deregulated as lung, colon, skin, prostate, and breast malignancies. In this article we will review which PKC isoforms are deregulated in different human cancers and summarize the mechanism of action of some of the major PKC modulators, analyzing the strengths and weaknesses of each one in the clinical setting.
Export Options
About this article
Cite this article as:
Coluccio Leskow F., A. Krasnapolski M. and J. Urtreger A., The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798376950
DOI https://dx.doi.org/10.2174/138920111798376950 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Glioma Dynamics and Computational Models: A Review of Segmentation, Registration, and In Silico Growth Algorithms and their Clinical Applications
Current Medical Imaging Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
CNS & Neurological Disorders - Drug Targets The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry CPP-Based Bioactive Drug Delivery to Penetrate the Blood-Brain Barrier: A Potential Therapy for Glioblastoma Multiforme
Current Drug Targets A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers
Current Cancer Drug Targets Production of Retroviral Vectors: Review
Current Gene Therapy Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Application of Machine Learning in Animal Disease Analysis and Prediction
Current Bioinformatics Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Assessment In Vitro of a Novel Therapeutic Strategy for Glioma, Combining Herpes Simplex Virus HSV1716-mediated Oncolysis with Gene Transfer and Targeted Radiotherapy
Medicinal Chemistry Kernelized Convex Hull based Collaborative Representation for Tumor Classification
Current Proteomics Application of NMR to the Study of Cells and Body Fluids
Current Organic Chemistry Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation
Current Molecular Medicine Current Overview of Inorganic Nanoparticles for the Treatment of Central Nervous System (CNS) Diseases
Current Nanomaterials Targeting the BRCA1/2 Tumor Suppressors
Current Drug Targets Applications of Molecular Imaging in Cancer Gene Therapy
Current Gene Therapy